TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical (OTCQB: TOMDF) announced the validation of its PCR-based Wound and Respiratory Pathogen panels at its CLIA/CAP-certified lab, Provista Diagnostics. The Wound Panel tests for 31 pathogens from wound samples, while the Respiratory Pathogen Panel assesses 24 pathogens from nasal or saliva samples. Provista aims to increase testing capacity from 25,000 to 50,000 PCR tests daily. Additionally, validation for MonkeyPox assays is scheduled for completion in August, with plans to include testing for MonkeyPox in both panels. This could significantly impact market growth, especially considering the rising need due to the MonkeyPox outbreak.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a collaboration with RTHM to evaluate the Tollovid™ 3CL protease inhibitor in patients suffering from Long COVID. The partnership has received its first commercial patient samples for a Long COVID Panel, which will assist in monitoring immune responses. Biomarker data from this panel will support the ongoing case studies for Tollovid, aiming to optimize treatment recommendations. The tests are covered by commercial insurance and Medicare, expanding access for patients. This initiative may enhance understanding of effective Long COVID treatments.

Todos Medical has initiated a validation plan for PCR-based MonkeyPox testing at its CLIA/CAP-certified lab, Provista Diagnostics. They are validating multiple PCR assays, focusing on both lesion and saliva sample collections. Saliva-based testing could enable earlier diagnosis for asymptomatic or early-stage patients at high risk. The company’s efforts are backed by a recent peer-reviewed publication highlighting the sensitivity of saliva testing. Todos is aiming to enhance MonkeyPox testing capacity amid rising health concerns.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a case study from its joint venture 3CL Pharma, detailing that Tollovid™ resolved COVID rebound symptoms post-Paxlovid treatment in a patient with Long COVID. The study highlights the efficacy of Tollovid, a botanical immune support supplement, in conjunction with antiviral treatments like Paxlovid. Tollovid is noted for its strong 3CL protease inhibition, outperforming Ivermectin. Todos continues to develop other therapeutic candidates, including Tollovir® for COVID-19 and diagnostic tests aiming for early cancer detection.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a partnership with Amerimmune Diagnostics to enhance its Long COVID diagnostic capabilities. Provista Diagnostics, Todos' laboratory, will utilize Amerimmune's immune panels to evaluate patients with acute and long-COVID. Tests will be insured and assess immune responses and antibody production against SARS-CoV-2. The partnership aims to improve patient outcomes by identifying immune system integrity for better treatment interventions, including eligibility for Evusheld® therapy.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its joint venture 3CL Pharma Ltd. released a case study on the effects of the 3CL protease inhibitors Paxlovid® and Tollovid™ on a patient suffering from Long COVID for 27 months. Following a 5-day treatment with Paxlovid, the patient experienced significant improvement after using Tollovid for over 30 days, increasing antibody inhibition levels by 30%. This study highlights the potential of Tollovid in addressing Long COVID symptoms, amidst rising global health concerns over COVID-19.

Todos Medical, Ltd. (OTCQB: TOMDF) announced outcomes from a case study on a patient suffering from Post-Acute Sequelae of COVID (Long COVID) who was treated with Tollovid®. The 32-year-old female patient experienced various severe symptoms after COVID-19 infection and saw significant improvement after a regimen of Tollovid. The study suggests that unaddressed COVID-19 pathologies may exist, reinforcing the value of Tollovid as a potential treatment for residual symptoms.

Todos Medical, Ltd. (OTCQB: TOMDF) announced positive biomarker data from its majority-owned joint venture 3CL Pharma Ltd.’s Phase 2 clinical trial of Tollovir™ for COVID-19 patients. The data indicates a strong correlation between key biomarkers and improved clinical outcomes. An open label extension study will enroll 46 patients to further support a U.S. FDA EUA application. The company noted a significant rise in COVID-19 hospitalizations, which may enhance the urgency and relevance of the ongoing research and its potential regulatory submissions.

Todos Medical, Ltd. (OTCQB: TOMDF) released preliminary data from a market research study on its dietary supplement, Tollovid®, showing high satisfaction among respondents. Among 41 participants, 83% of those with acute COVID and 68% with long COVID reported satisfaction. Key findings include a 100% overall satisfaction for acute COVID users and up to 91.6% symptom improvement in short long COVID. Reported side effects were minimal, with dark stool in 17% of users. The company plans to utilize these findings to enhance product offerings and inform future clinical trials for its therapeutic candidate, Tollovir™.